Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post by Misty Dawn Shields, Assistant professor of clinical medicine at Indiana University, on X, adding:
“Big Tarlatamab Monitoring Update
For C1D1 + C1D8: observation from 22-24 hours to 6-8 hours.
Stay within 1 hour of appropriate healthcare for 48 hours.
Follow-up assessment on Days 2 + 9 Much more practical for patients.”
Quoting Misty Dawn Shields:
“Amgen Oncology received approval on September 14, 2026 to reduce the recommended monitoring period for tarlatamab, which is currently FDA approved for the 2L setting for ES-SCLC.
Specifically, this approved label update reduces the recommended monitoring for cycle 1 day 1 and day 8 of tarlatamab:
- observation from 22-24 hours to 6-8 hours
- vital signs and assessment follow up on the subsequent day (days 2 and 9)
Note: Patients should remain within 1 hr of the appropriate healthcare setting for 48 hrs, following cycle 1 day 1 and day 8, and care partner support is encouraged.
These vital updates help our SMASHERS gain improved access to life-changing therapeutics by reducing barriers, such as need for hospitalization for administration and monitoring.
Unmet need: Validated risk assessment tools will be helpful to identify those who may be at risk for high grade CRS and early interventions.”
Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, also added:
“Say not more. Being able to give a tarlatamab for SCLC without requiring an overnight admission will be a game changer for patients and increase access treatment .
There is still a lot of time toxicity w 6-8 hrs observations- DeLLphi309 data presented at WCLC26 on extended treatment intervals is welcomed.”
You may also find this interesting:
DeLLphi-305: Durvalumab + Tarlatamab Improves Survival in First-Line ES-SCLC
